Table 1.

Summary of various MT-targeting agents applied to protect the nervous system.

Classification	Compound	Pathological model	Outcome	Ref.
MSAs	Paclitaxel (Taxol)	SCI	Enhancement of nerve regeneration and functional recovery	[119, 120]
		Retinal nerve injury	Increased MT numbers and stabilization to restore axonal transport	[121]
		AD	Improvements in axonal transport, tissue, and motor function	[122]
	Epothilones	SCI	Decreased scarring, increased axon regeneration, and improved motor function	[102, 103]
		PD	Rescued MT defects and attenuated nigrostriatal degeneration	[123]
		AD	Reduced axonal dystrophy, increased axonal MT density, improved speed of axonal transport, and improved cognitive performance	[124, 125]
	Davunetide (NAP)	AD, ALS	Prevented axonal transport disruption, synaptic defects, and behavioral impairments	[126, 127]
MDAs	Vincristine	iPSC-derived neurons from HSP patients	Ameliorated axonal swelling	[128]
	Okadaic acid	Hyperphosphorylated Tau to model AD	Reduced the growth of the rat cortical neuron axons	[129]